HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors.
Barros MJ, Strosberg J, Al-Toubah T, de Jesus VHF, Durant L, Mello CA, Felismino TC, De Brot L, Taboada RG, Donadio MD, Riechelmann RP.
Barros MJ, et al. Among authors: felismino tc.
Ther Adv Med Oncol. 2023 Jul 29;15:17588359231186041. doi: 10.1177/17588359231186041. eCollection 2023.
Ther Adv Med Oncol. 2023.
PMID: 37529158
Free PMC article.